MXPA04003944A - Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto. - Google Patents

Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.

Info

Publication number
MXPA04003944A
MXPA04003944A MXPA04003944A MXPA04003944A MXPA04003944A MX PA04003944 A MXPA04003944 A MX PA04003944A MX PA04003944 A MXPA04003944 A MX PA04003944A MX PA04003944 A MXPA04003944 A MX PA04003944A MX PA04003944 A MXPA04003944 A MX PA04003944A
Authority
MX
Mexico
Prior art keywords
subject
ghrh
cells
functional biological
nucleic acid
Prior art date
Application number
MXPA04003944A
Other languages
English (en)
Inventor
J Schwartz Robert
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MXPA04003944A publication Critical patent/MXPA04003944A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion pertenece a un metodo para reducir la proporcion de grasa corporal, incrementar la masa corporal fina ("LMB"), incrementar la densidad osea, o mejorar la velocidad de curacion osea, o todos, de un sujeto. En resumen, las modalidades de la invencion pueden realizarse al suministrar una secuencia de acidos nucleicos heterologa que codifica GHRH o equivlente biologico funcional de la misma en las celulas del sujeto y permitir que ocurra la expresion del gen codificado mientras las celulas modificadas se encuentran dentro del sujeto. Por ejemplo, cuando tal secuencia de acidos nucleicos se suministra en las celulas especificas del tejido del sujeto, se logra expresion constitutiva especifica. Ademas, la regulacion externa de GHRH o gen equivlente biologico funcional del mismo puede realizarse al utilizar promotores inducibles que se regulan por las moleculas de cambio molecular, que se dan al sujeto. El metodo preferido para suministrar las secuencias de codificacion de acidos nucleicos inducibles o constitutivas de GHRH o los equivalentes biologicos funcionales de las mismas es directamente en las celulas del sujeto por el proceso de electroporacion in vivo. Una reduccion de la proporcion de grasa corporal y un incremento en la masa corporal fina ("LMB") o ambas de un sujeto se logra por el suministro de GHRH o equivalente biologico funcional de la misma como se describe en la presente en el sujeto como proteinas recombinantes. Ademas, un incremento en la densidad osea y mejora en la velocidad de curacion osea tambien se logra.
MXPA04003944A 2001-10-26 2002-10-25 Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto. MXPA04003944A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35780801P 2001-10-26 2001-10-26
PCT/US2002/034275 WO2003038112A2 (en) 2001-10-26 2002-10-25 A composition and method to alter lean body mass and bone properties in a subject

Publications (1)

Publication Number Publication Date
MXPA04003944A true MXPA04003944A (es) 2004-07-08

Family

ID=23407110

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04003944A MXPA04003944A (es) 2001-10-26 2002-10-25 Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.

Country Status (10)

Country Link
US (2) US7338656B2 (es)
EP (1) EP1450605B1 (es)
CN (1) CN100417419C (es)
AR (1) AR037038A1 (es)
AT (1) ATE536100T1 (es)
AU (1) AU2002348417B9 (es)
BR (1) BR0213965A (es)
CA (1) CA2464199C (es)
MX (1) MXPA04003944A (es)
WO (1) WO2003038112A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
US7440806B1 (en) * 2000-11-21 2008-10-21 Boston Scientific Neuromodulation Corp. Systems and methods for treatment of diabetes by electrical brain stimulation and/or drug infusion
US7493171B1 (en) * 2000-11-21 2009-02-17 Boston Scientific Neuromodulation Corp. Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion
EP1578901A4 (en) * 2001-09-07 2006-03-29 Baylor College Medicine LINEAR DNA FRAGMENTS FOR GENE EXPRESSION
EP1499731B1 (en) * 2002-02-07 2011-05-25 Baylor College Of Medicine Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
WO2005073371A2 (en) * 2004-01-20 2005-08-11 Advisys, Inc. Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US7846720B2 (en) * 2005-01-26 2010-12-07 Vgx Pharmaceuticals, Inc. Optimized high yield synthetic plasmids
CN1313494C (zh) * 2005-08-29 2007-05-02 中国人民解放军军事医学科学院生物工程研究所 一种具有促增长作用的融合蛋白及其编码基因与应用
CA2632970C (en) * 2006-01-03 2012-01-24 Steven W. Kovalcheck System for dissociation and removal of proteinaceous tissue
US20110118729A1 (en) * 2009-11-13 2011-05-19 Alcon Research, Ltd High-intensity pulsed electric field vitrectomy apparatus with load detection
US20110118734A1 (en) * 2009-11-16 2011-05-19 Alcon Research, Ltd. Capsularhexis device using pulsed electric fields
US20110135626A1 (en) * 2009-12-08 2011-06-09 Alcon Research, Ltd. Localized Chemical Lysis of Ocular Tissue
US20110144562A1 (en) * 2009-12-14 2011-06-16 Alcon Research, Ltd. Localized Pharmacological Treatment of Ocular Tissue Using High-Intensity Pulsed Electrical Fields
WO2011081897A1 (en) * 2009-12-15 2011-07-07 Alcon Research, Ltd. High-intensity pulsed electric field vitrectomy apparatus
US8546979B2 (en) 2010-08-11 2013-10-01 Alcon Research, Ltd. Self-matching pulse generator with adjustable pulse width and pulse frequency
EP2616095A4 (en) * 2010-09-16 2014-03-19 Univ Miami ACCELERATING WOUND HEALING WITH HORMONE FOR RELEASE OF GROWTH HORMONE AND AGONISTS
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
CN105671139A (zh) * 2014-11-17 2016-06-15 武汉白原科技有限公司 人体lbm（瘦体重）检测试剂盒和方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223019A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) 1979-03-30 1980-09-16 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4228156A (en) 1979-03-30 1980-10-14 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) 1979-03-30 1980-10-07 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) 1981-12-28 1983-10-18 Beckman Instruments, Inc. Combinations having synergistic pituitary growth hormone releasing activity
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US5134120A (en) 1984-08-03 1992-07-28 Cornell Research Foundation, Inc. Use of growth hormone to enhance porcine weight gain
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4833166A (en) 1987-05-01 1989-05-23 Grosvenor Clark E Growth hormone releasing hormone complementary peptides
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
USRE33699E (en) 1987-07-09 1991-09-24 International Minerals & Chemical Corp. Growth hormone-releasing factor analogs
FR2622455B1 (fr) 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5023322A (en) 1988-08-31 1991-06-11 Mta Kutatas-Es Szervezetelemzo Intezete Analogs of growth hormone releasing factor (GRF) and a method for the preparation thereof
US5084442A (en) 1988-09-06 1992-01-28 Hoffmann-La Roche Inc. Cyclic growth hormone releasing factor analogs and method for the manufacture thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5137872A (en) 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
WO1991011522A1 (en) 1990-01-26 1991-08-08 Baylor College Of Medicine MUTATED PROMOTER REGION FROM CHICKEN SKELETAL α-ACTIN GENE
AU656144B2 (en) 1990-06-29 1995-01-27 F. Hoffmann-La Roche Ag Histidine substituted growth hormone releasing factor analogs
US5486505A (en) 1990-07-24 1996-01-23 Polygen Holding Corporation Polypeptide compounds having growth hormone releasing activity
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1992018531A1 (en) 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5298422A (en) 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
JP3368603B2 (ja) 1992-02-28 2003-01-20 オリンパス光学工業株式会社 遺伝子治療用処置具
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5507724A (en) 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
HUT70467A (en) 1992-07-27 1995-10-30 Pioneer Hi Bred Int An improved method of agrobactenium-mediated transformation of cultvred soyhean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5655961A (en) 1994-10-12 1997-08-12 Acres Gaming, Inc. Method for operating networked gaming devices
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
CA2218173A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
AU6855796A (en) 1995-08-29 1997-03-19 Cbr Laboratories, Inc. In vivo electroporation of cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
US5704908A (en) 1996-10-10 1998-01-06 Genetronics, Inc. Electroporation and iontophoresis catheter with porous balloon
US6165755A (en) 1997-01-23 2000-12-26 University Of Victoria Innovation And Development Corporation Chicken neuropeptide gene useful for improved poultry production
CA2297375A1 (en) * 1997-07-24 1999-02-04 Valentis, Inc. Ghrh expression system and methods of use
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US6759393B1 (en) * 1999-04-12 2004-07-06 Pfizer Inc. Growth hormone and growth hormone releasing hormone compositions
US20040192593A1 (en) * 1999-07-26 2004-09-30 Baylor College Of Medicine Protease resistant ti-growth hormone releasing hormone
CA2378943C (en) * 1999-07-26 2012-09-18 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6486134B2 (en) 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
WO2001066149A2 (en) 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
AR035671A1 (es) * 2000-12-12 2004-06-23 Advisys Inc Administracion de secuencia de acido nucleico a un animal hembra, para aumentar el crecimiento de la descendencia
US20030074679A1 (en) * 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
CA2469310C (en) * 2001-12-11 2013-01-29 Advisys, Inc. Plasmid mediated supplementation for treating chronically ill subjects
US9302725B2 (en) 2013-03-14 2016-04-05 Bell Sports, Inc. Locking rack system for bicycles
WO2015178959A1 (en) 2014-05-19 2015-11-26 Felix Sorkin Modified permanent cap

Also Published As

Publication number Publication date
US20040138111A1 (en) 2004-07-15
WO2003038112A2 (en) 2003-05-08
US20090292107A1 (en) 2009-11-26
US7338656B2 (en) 2008-03-04
AR037038A1 (es) 2004-10-20
BR0213965A (pt) 2005-03-15
AU2002348417B2 (en) 2009-10-01
EP1450605A2 (en) 2004-09-01
CA2464199C (en) 2013-12-24
EP1450605A4 (en) 2007-01-17
ATE536100T1 (de) 2011-12-15
CN100417419C (zh) 2008-09-10
WO2003038112A3 (en) 2003-11-06
EP1450605B1 (en) 2011-12-07
CA2464199A1 (en) 2003-05-08
CN1649496A (zh) 2005-08-03
AU2002348417B9 (en) 2010-02-04
WO2003038112B1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
MXPA04003944A (es) Una composicion y metodo para alterar la masa corporal fina y propiedades oseas en un sujeto.
BE2014C077I2 (es)
MY142457A (en) Plasmid mediated supplementation for treating chronically ill subjects
HK1025789A1 (en) Recombinant vascular endothelial cell growth factor d (vegf-d)
WO2003023000A3 (en) Linear dna fragments for gene expression
WO2004064750A3 (en) Improved constructs for expressing lysosomal polypeptides
ATE460183T1 (de) Viraler vektor zur verwendung in der in-vivo- gentherapie von morbus parkinson
DE69731660D1 (de) Insulinähnlicher wachstumfaktor i (igf-i) expressionssystem und methode zur verwendung
HUP9904219A2 (hu) Eljárás és készítmények interferon-alfa-nukleinsavak bevitelére és expressziójára
DE60028217D1 (de) Zyklische depsipeptid-synthasen, deren gene und system zur massenproduktion von zyklischen depsipeptiden
WO2004093920A3 (en) Ghrh for use in treating chronic renal failure
WO2002068629A3 (en) Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
WO2003012121A3 (en) Collagen xxii, a novel human collagen and uses thereof
WO2002018556A3 (en) 8797, a human galactosyltransferase and uses thereof
TH78121B (th) สารผสมและวิธีเปลี่ยนแปลงมวลร่างกายในคนผอมและคุณสมบัติของกระดูกในผู้เข้ารับการทดลอง
TH78121A (th) สารผสมและวิธีเปลี่ยนแปลงมวลร่างกายในคนผอมและคุณสมบัติของกระดูกในผู้เข้ารับการทดลอง
AU2002359572A8 (en) 15603, a human ion channel family member
EP1679372A4 (en) NEW PLEXIN POLYPEPTIDE, THIS CODING DNA AND USE THEREOF
WO2002044357A3 (en) Methods of using 18903 to treat pain and pain-related disorders
MX2023003021A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
WO2001081586A3 (en) 21657, a human short-chain dehydrogenase and uses thereof
AU2002352068A1 (en) 2150, a human protein kinase family member and uses therefor
Zuohua et al. Construction of eukaryotic expressing vector pCH503 of CH50 and its chemotaxis and anti-tumor function by expression in vivo in mice
MX9806628A (es) Gen de respuesta de diferenciacion terminal mieloide humana novedoso.
WO2002018582A3 (en) 62112, a novel human dehydrogenase and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration